5-Lipoxygenase pharmacological blockade decreases tau phosphorylation in vivo: Involvement of the cyclin-dependent kinase-5

Neurobiology of Aging

Volumn 34, Issue 6, 2013, Pages 1549-1554

  Chu, Jin ^a   Praticò, Domenico ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 Lipoxygenase; Alzheimer's disease; Beta amyloid; Tau protein; Transgenic mouse models

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; BRAIN PROTEIN; CYCLIN DEPENDENT KINASE 5; EPITOPE; PHOSPHOTRANSFERASE; SERINE; TAU PROTEIN; THREONINE; ZILEUTON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; HUMAN; IN VIVO STUDY; MOUSE; NERVE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

ANIMALS; ARACHIDONATE 5-LIPOXYGENASE; BRAIN; CYCLIN-DEPENDENT KINASE 5; FEMALE; HUMANS; HYDROXYUREA; LIPOXYGENASE INHIBITORS; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; RANDOM ALLOCATION; TAU PROTEINS;

EID: 84875271571     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2012.12.009     Document Type: Article

References (21)

1. Berger W., De Chandt M.T.M., Cairns C.B. Zileuton: clinical implications of 5-Lipoxyegnase inhibition in severe airways disease. Int. J. Clin. Pract. 2007, 61:663-676.
2. Chu J., Giannopoulos P.F., Ceballos-Diaz C., Golde T.E., Praticò, D. 5-Lipoxygenase gene transfer worsens memory, amyloid and tau brain pathologies in a mouse model of Alzheimer disease. Ann. Neurol. 2012, 72:442-454.
3. Chu J., Giannopoulos P.F., Ceballos-Diaz C., Golde T.E., Praticò D. Adeno-associated virus brain deliver of 5-lipoxygenase modulates the AD-like phenotype of APP mice. Mol. Neurodeger. 2012, 7:1.
4. Chu J., Praticò D. 5-Lipoxygenase as an endogenous modulator of amyloid-beta formation in vivo. Ann. Neurol. 2011, 69:34-46.
5. Chu J., Praticò D. Pharmacologic blockade of 5-Lipoxygenase improves the amyloidotic phenotype of an AD transgenic mouse model: involvement of γ-secretase. Am. J. Pathol. 2011, 178:1762-1769.
6. Firuzi O., Zhou J., Chinnici C.M., Wisnieski T., Praticò D. Five-Lipoxygenase gene disruption reduces amyloid-{beta} pathology in a mouse model of Alzheimer's disease. FASEB J. 2008, 22:1169-1178.
7. Geschwind D.H. Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg?. Neuron 2003, 40:457-460.
8. Hernández F., Avila J. Tauopathies. Cell Mol. Life Sci. 2007, 64:2219-2233.
9. Humbert S., Dhavan R., Tsai L. P39 activates cdk5 in neurons, and is associated with the actin cytoskeleton. J. Cell Sci. 2000, 113:975-983.
10. Iqbal K., Liu F., Gong C.X., Grundke-Iqbal I. Tau in Alzheimer disease and related tauopathies. Curr. Alzheimer Res. 2010, 7:656-664.
11. Joshi Y., Chu J., Praticò D. Stress hormone leads to memory deficits and altered tau phosphorylation in a mouse model of Alzheimer's disease. J. Alzheimers Dis. 2012, 31:167-176.
12. Kitazawa M., Oddo S., Yamasaki T.R., Green K.N., Laferla F. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J. Neurosci. 2005, 25:8843-8853.
13. Lee M.S., Tsai L.H. Cdk5: one of the links between senile plaques and neurofibrillary tangles?. J. Alzheimers Dis. 2003, 5:127-137.
14. Liu S.J., Zhang A.H., Li H.L., Wang Q., Deng H.M., Netzer W.J., Xu H., Wang J.Z. Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J. Neurochem. 2003, 87:1333-1344.
15. Maldonado H., Ramírez E., Utreras E., Pando M.E., Kettlun A.M., Chiong M., Kulkarni A.B., Collados L., Puente J., Cartier L., Valenzuela M.A. Inhibition of cyclin-dependent kinase 5 but not of glycogen synthase kinase 3-β prevents neurite retraction and tau hyperphosphorylation caused by secretable products of human T-cell leukemia virus type I-infected lymphocytes. J. Neurosci. Res. 2011, 89:1489-1498.
16. Mederios R., Baglietto-Vargas D., Laferla F. The role of tau in Alzheimer's disease and related disorders. CNS Neurosci. Ther. 2011, 17:514-524.
17. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., Metherate R., Mattson M.P., Akbari Y., LaFerla F.M. Triple transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39:409-421.
18. Oddo S., Caccamo A., Tseng B., Cheng D., Vasilevko V., Cribbs D.H., LaFerla F.M. Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J. Neurosci. 2008, 28:12163-12175.
19. Querfurth H.W., Laferla F.M. Alzheimer's disease [erratum in 2011;364:588]. N. Engl. J. Med. 2010, 362:329-344.
20. Robertson E.D., Scearce-Levie K., Palop J.J., Yan F., Cheng I.H., Wu T., Gerstein H., Yu G.Q., Mucke L. Reducing endogenous tau ameliorates amyloid-beta-induced deficits in an Alzheimer's disease mouse model. Science 2007, 16:750-754.
21. Yang H., Zhuo J., Chu J., Chinnici C., Praticò D. Amelioration of the Alzheimer's disease phenotype by absence of 12/15-lipoxygenase. Biol. Psychiatry 2010, 68:922-929.